<DOC>
	<DOCNO>NCT00541697</DOCNO>
	<brief_summary>A study ass effectiveness tolerability MK0653A MK0653A versus Atorvastatin lower LDL-C level .</brief_summary>
	<brief_title>Eze/Simva Switch Study Diabetics ( 0653A-807 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Currently treat Atorvastatin 10 mg least 6 week Have Type 2 Diabetes Weight must stable 6 week enter study Consume 14 alcoholic drink per week . Pregnant lactating Have take another investigation drug within 3 month start study History congestive heart failure , heart attack , coronary artery bypass surgery Uncontrolled high blood pressure HIV positive History cancer last 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>